DBV Technologies (NASDAQ:DBVT) Shares Pass Above 50 Day Moving Average - What's Next?

Key Points

• DBV Technologies' shares have recently surpassed their 50-day moving average, trading at $9.82 after reaching a high of $10.38.
• Analysts have mixed views on the stock, with targets ranging from $7.25 by Goldman Sachs to $21.00 by JMP Securities, reflecting a consensus rating of "Moderate Buy".
• The company reported significant earnings miss at ($1.55) EPS, despite a revenue of $1.74 million that exceeded expectations for the quarter.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $9.57 and traded as high as $10.38. DBV Technologies shares last traded at $9.82, with a volume of 98,148 shares traded.

Analyst Upgrades and Downgrades

DBVT has been the subject of several analyst reports. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a research report on Thursday, May 29th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Finally, HC Wainwright raised their price objective on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. Two research analysts have rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $14.75.

DBV Technologies Stock Down 1.6%

The firm has a 50-day moving average price of $9.65 and a 200 day moving average price of $7.68. The firm has a market capitalization of $264.31 million, a PE ratio of -2.02 and a beta of -0.58.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. Equities research analysts expect that DBV Technologies S.A. will post -7.05 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.